Effect of Atorvastatin on Serum Levels of Periostin in Asthma - A Placebo Controlled Randomized Clinical Trial
Abstract Background: Asthma is a common pulmonary disease with a high morbidity rate. Considering the role of inflammation in the disease induction and severity, and the anti–inflammatory effect of atorvastatin, we aimed to investigate the effect of atorvastatin on serum level of periostin and eosinophil in patients with asthma, in order to introduce the usefulness of this drug on reducing the inflammation in patients with asthma.Methods: In a blinded randomized control trial, 80 patients with definite diagnosis of asthma were enrolled into the intervention or placebo group, who received 40 mg/day atorvastatin and similar placebo every day for 8 weeks. Spirometric measurements were performed and asthma control test was completed by the patients at baseline, after 4 weeks, and at the end of study (after 8 weeks). The primary outcomes of the study were serum eosinophil count and periostin levels. Results: 40 patients were analyzed in each group and their data were analyzed. Mean asthma control scores in the intervention and placebo groups were similar at baseline (17.95±3.75 vs. 17.98±3.77; P>0.05) and improved in the intervention group (19.88±3.28; P<0.001), but remained unchanged in the placebo group (18.6±3.26; P=0.09). Neither the spirometric changes, nor the serum levels of eosinophil count and periostin were significantly different between the groups (P>0.05).Conclusions: Although the intervention group had improved asthma control score after the intervention, this effect could be because of the indirect effect of atorvastatin, as the spirometric measurements and inflammatory markers did not change significantly and were not different between the placebo and intervention groups. Further studies with longer follow-ups may show changes in spirometric parameters by atorvastatin or its effect on other inflammatory markers.